Angelo Gambi

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study

Dino Amadori, Oriana Nanni, M. Marangolo et al. · Journal of Clinical Oncology · 2000 · 58 citations

Medicine, Oncology, Pharmacology +17

Attributable mortality of carbapenem-resistant Klebsiella pneumoniae infections in a prospective matched cohort study in Italy, 2012–2013

Ana Hoxha, Tommi Kärki, Cristina Giambi et al. · Journal of Hospital Infection · 2015 · 55 citations

Life Sciences, Infectious Diseases, Antimicrobial Resistance +16

Role of biological markers in the clinical outcome of colon cancer

Oriana Nanni, Annalisa Volpi, Giovanni Luca Frassineti et al. · British Journal of Cancer · 2002 · 51 citations · Full text

Medicine, Oncology, Pathology +17

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Jean‐François Emile, Catherine Julié, Karine Le Malicot et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Immunology, Oncology +17